21:52 , Sep 18, 2018 |  BC Extra  |  Company News

Management tracks: BioTime, Immune-Onc

Degenerative disease company BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX) named Brian Culley CEO, to replace co-CEOs Adi Mohanty and Michael West. Most recently, Culley was CEO of infectious disease company Artemis Therapeutics Inc. (OTCQB:ATMS). Immunotherapy company Immune-Onc...
21:08 , Aug 2, 2018 |  BC Extra  |  Company News

Management tracks: Omeros, EdiGene

Omeros Corp. (NASDAQ:OMER) hired Eckhard Leifke as CMO and VP of clinical development. He was global project head/VP of early project and external opportunities - cardiovascular and metabolism and global head/VP of late-stage development diabetes...
22:19 , Jul 19, 2018 |  BC Innovations  |  Translation in Brief

Public Funding Highlights: 2Q18

Public Funding Highlights: 2Q18 Selected developments and initiatives in 2Q18 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI) and the Canadian...
22:27 , Jul 16, 2018 |  BC Extra  |  Financial News

Malin appoints Curley as chairman

Life sciences investing company Malin Corp. plc (ISE:MLC) appointed Ian Curley as chairman. He was CEO at packaging company Ardagh Group S.A. (NYSE:ARD). Malin provides capital and operational expertise to small life science businesses. Its portfolio...
00:59 , Jun 30, 2018 |  BioCentury  |  Regulation

Not a test

Antibiotics developers shouldn’t read too much into FDA’s rejection of the first drug to be reviewed under a new limited-use pathway that is supposed to make it easier to develop treatments for rare and resistant...
15:03 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

FDA approves plazomicin for cUTI, but not blood infections

Achaogen Inc. (NASDAQ:AKAO) said FDA approved Zemdri plazomicin to treat complicated urinary tract infections (cUTIs), but issued a complete response letter for the same candidate to treat bloodstream infections. The mixed decision is in line...
15:30 , Jun 26, 2018 |  BC Extra  |  Company News

FDA approves plazomicin for cUTI, but not blood infections

Achaogen Inc. (NASDAQ:AKAO) said FDA approved Zemdri plazomicin to treat complicated urinary tract infections (cUTIs), but issued a complete response letter for the same candidate to treat bloodstream infections. The mixed decision is in line...
19:13 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Melinta closes $123.2M follow-on

Anti-infectives company Melinta Therapeutics Inc. (NASDAQ:MLNT) raised $123.2 million through the sale of 24.6 million shares at $5 in a follow-on underwritten by J.P. Morgan, Jefferies and Cantor Fitzgerald. The figures include the sale of...
17:14 , May 24, 2018 |  BC Extra  |  Financial News

Melinta raises $110M in follow-on

Anti-infectives company Melinta Therapeutics Inc. (NASDAQ:MLNT) raised $110 million through the sale of 22 million shares at $5 in a follow-on underwritten by J.P. Morgan, Jefferies and Cantor Fitzgerald. The price is a 32% discount...
01:16 , Mar 30, 2018 |  BC Innovations  |  Finance

Bug money

Despite the tremendous public health need and the introduction of regulatory incentives including expedited review and market exclusivity, venture investing in antibiotics remains modest and focused primarily on clinical assets seeking to improve on known...